25 Aug. 2014
WILMINGTON, N.C. (August 25, 2014) – Pharmaceutical Product Development, LLC (PPD) today announced the appointment of Robert Hureau as executive vice president and chief financial officer. Hureau brings 25 years of experience and extensive financial expertise spanning the medical technology/life sciences, manufacturing and consumer sectors. Hureau begins his new role on Sept. 23 and will be based in PPD’s headquarters in Wilmington.
“Bob is an accomplished chief financial officer who will uphold PPD’s long-standing reputation as a company committed to integrity, financial discipline and sustainable growth,” said David Simmons, PPD’s chairman and chief executive officer. “We are confident Bob’s experience, strong business mind and financial acumen will complement and aid PPD's focus on delivering value for our biopharmaceutical clients.”
Hureau joined PPD from Centaur Guernsey L.P. Inc., a leading global medical technology company focused on transformational healing solutions, where he served as executive vice president and CFO. Previously, he held a series of senior leadership positions of increasing responsibility, including senior vice president and CFO at Sensata Technologies N.V., a supplier of sensing, electrical protection, control and power management solutions, and vice president of finance with The Jean Coutu Group (PJC) U.S.A., Inc., chain of retail pharmacies. In addition, Hureau’s experience includes financial leadership responsibilities with Ocean Spray Cranberries, Inc., and other companies in the consumer sector. Hureau is a certified public accountant and began his career at Coopers & Lybrand.
PPD is a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and approximately 13,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments.
+1 919 456 5350
+1 910 558 7585